Zydus Lifesciences
Date : 23.02.2025
Zydus
Timeframe : Weekly
Strengths
1 Good profit growth of 32.60% for the Past 3 years.
2 Healthy Interest coverage ratio of 11.85.
3 Maintaining an effective average operating margins of 27.25% in the last 5 years.
4 Company’s PEG ratio is 0.16.
5 Has an efficient Cash Conversion Cycle of 45.65 days.
6 Company has a healthy liquidity position with current ratio of 2.22.
7 The company has a high promoter holding of 74.98%
Latest Update :
RECEIVES FINAL APPROVAL FROM USFDA FOR IBUPROFEN AND FAMOTIDINE TABLETS, 800 MG/26.6 MG
Regards,
Ankur
Zydus
Timeframe : Weekly
Strengths
1 Good profit growth of 32.60% for the Past 3 years.
2 Healthy Interest coverage ratio of 11.85.
3 Maintaining an effective average operating margins of 27.25% in the last 5 years.
4 Company’s PEG ratio is 0.16.
5 Has an efficient Cash Conversion Cycle of 45.65 days.
6 Company has a healthy liquidity position with current ratio of 2.22.
7 The company has a high promoter holding of 74.98%
Latest Update :
RECEIVES FINAL APPROVAL FROM USFDA FOR IBUPROFEN AND FAMOTIDINE TABLETS, 800 MG/26.6 MG
Regards,
Ankur
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.